Who are Prontogest 400 mg vaginal pessaries's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Progesterone, PROGESTERONE, Medical abortion, Lutinus + transfer day 7, Endometrin, Lutinus + transfer day 6.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/prontogest-400-mg-vaginal-pessaries.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Prontogest 400 mg vaginal pessaries — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prontogest 400 mg vaginal pessaries (Prontogest 400 mg vaginal pessaries) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Progesterone. Area: Gastroenterology.

marketed Progesterone Uterine smooth muscle and cervical tissue Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Prontogest 400 mg vaginal pessaries (Prontogest 400 mg vaginal pessaries) — Ain Shams Maternity Hospital. Prontogest 400 mg vaginal pessaries work by delivering progesterone to the vaginal mucosa, which helps maintain uterine quiescence and prevent preterm labor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prontogest 400 mg vaginal pessaries TARGET	Prontogest 400 mg vaginal pessaries	Ain Shams Maternity Hospital	marketed	Progesterone	Uterine smooth muscle and cervical tissue
Progesterone	Progesterone plus HCG	Dunamenti REK Istenhegyi IVF Center	marketed	Progesterone [EPC]	progesterone receptor, luteinizing hormone/choriogonadotropin receptor	1978-01-01
PROGESTERONE	PROGESTERONE		marketed	Progesterone [EPC]		1976-01-01
Medical abortion	Medical abortion	Reproductive Health Training Center of the Republic of Moldova	marketed	Progesterone receptor antagonist + prostaglandin analog combination	Progesterone receptor (PR); prostaglandin receptors (EP1, EP2, EP3, FP)
Lutinus + transfer day 7	Lutinus + transfer day 7	Anja Bisgaard Pinborg	marketed	Progesterone supplement	Progesterone receptor
Endometrin	progesterone	Ferring	marketed	Progesterone [EPC]	Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1
Lutinus + transfer day 6	Lutinus + transfer day 6	Anja Bisgaard Pinborg	marketed	Progesterone supplement	Progesterone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-02-03 — Endometrin · 10548904 · Method of Use · US
2029-02-03 — Endometrin · 10537584 · Formulation · US
2030-01-21 — Endometrin · 8580293 · Method of Use · US

Sponsor landscape (Progesterone class)

Ain Shams Maternity Hospital · 1 drug in this class
Lee's Pharmaceutical Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prontogest 400 mg vaginal pessaries — Competitive Intelligence Brief. https://druglandscape.com/ci/prontogest-400-mg-vaginal-pessaries. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab